Per Soelberg Sørensen
|
|
- Earl Miles
- 5 years ago
- Views:
Transcription
1 Per Soelberg Sørensen Danish Multiple Sclerosis Center Department of Neurology Rigshospitalet, University of Copenhagen Copenhagen, Denmark Declared receipt personal compensation for serving on scientific advisory boards, steering committees or independent data monitoring boards for Biogen Idec, Merck, Novartis, Genzyme, Teva Pharmaceutical Industries Ltd., Glaxo SmithKlime, medday Pharmaceuticals and Forward Pharma. He declared receipt of honoraria from Biogen Idec, Merck, Teva Pharmaceutical Industries Ltd., Genzyme and Novartis. His department received support from Biogen Idec, Merck, Teva, Sanofi-Aventis, Genzyme, Novartis, Bayer, RoFAR, Roche, the Danish Multiple Sclerosis Society, the Danish Medical Research Council and the European Union Sixth Framework Programme
2 Selecting optimal therapy in relapsing MS: balancing efficacy and burden of therapy More effective, with limited burden More effective, but increased burden Efficacy: Relapses Disability MRI activity MRI atrophy Less effective, but limited burden Less effective, with increased burden Burden of Therapy: Convenience Monitoring Tolerability Safety 2 2
3 Evolution in disease-modifying drugs for relapsingremitting multiple sclerosis Fingolimod Teriflunomide Alemtuzumab Dimethyl fumarate 2000 Natalizumab Mitoxantrone Glatiramer acetate Interferon-beta (1b and 1a)
4 Disease-modifying drugs: Benefit/risk evaluation Established Inconveniences and Risks Convenience Monitoring Tolerability Safety Established Benefits efficacy Risk Minimization
5 Interferon-beta: benefit/risk evaluation Established Inconveniences and Possible Risks Injectables Frequent s.c. or i.m. injections Trivial side effects Flu-like symptoms (IFNβ) Injection site reactions Neutralizing Antibodies (NAbs) Established Benefits Moderate effect on disease activity (on average 30% reduction in relapse rate) Less effect on disability progression Excellent response in approximately 30% of patients No long-term safety concerns
6 Recommendations for Maximizing Tolerance and Safety of Interferon-beta Within 3 months CBC LFT MRI Counsel patients to Report adverse effects Use contraception Report pregnancy Prior to Initiating Initiation During Discontinuation Inform patients about possible adverse effects Treat flu-like symptoms with paracetamol or ibuprophen Measure NAbs after 6, 12 and 24 months Repeat NAb measurements if positive In case of confirmed high level NAbs switch to another therapy. With confirmed moderate level NAbs measure in vivo MxA response to IFN-beta Monitor CBC and LFT If LFT > 3 times upper normal level reduce dose or pause therapy Discontinue therapy if pregnancy occurs Switch to another therapy if unacceptable adverse effect MRI yearly Escalate therapy to a second-line therapy if suboptimal treatment response For alternative treatment: Direct switch to immunomodulator possible CBC: complete blood cell count; LFT: Liver function tests; MRI: Magnetic resonance imaging; NAbs: neutralizing antibodies; MxA: Myxovirus A
7 Glatiramer acetate: benefit/risk evaluation Established Inconveniences and Possible Risks Injectables Daily injections may decrease adherence Trivial side effects Injection site reactions Systemic reactions Established Benefits On average a moderate effect on disease activity (30% reduction in relapse rate) Less effect on disability progression Excellent response in approximately 30% of patients No long-term safety concerns
8 Recommendations for Maximizing Tolerance and Safety of Glatiramer Acetate Within 3 months CBC MRI Counsel patients to Report adverse effects Use contraception Report pregnancy Prior to Initiating Initiation During Discontinuation Inform patients about possible adverse effects Discontinue therapy if pregnancy occurs Switch to another therapy if unacceptable adverse effect MRI yearly Escalate therapy to a second-line therapy if suboptimal treatment response For alternative treatment: Direct switch to immunomodulator possible CBC: complete blood cell count; MRI: Magnetic resonance imaging;
9 Teriflunomide: benefit/risk evaluation Established Inconveniences and Possible Risks Adverse effects Diarrhoea and nausea Hair thinning ALT increase Potentially immunosuppressive properties Established Benefits Moderate effect on disease activity Moderate effect on disability progression Equal to IFN-β 1a SC One tablet daily
10 Recommendations for Maximizing Tolerance and Safety of Teriflunomide Within 3 months CBC LFT MRI Negative pregnancy test before initiation of therapy in women with child-bearing potential Counsel patients to Report symptoms of infection Report adverse effects Use contraception/avoid pregnancy Prior to Initiating Initiation During Discontinuation Inform patients about possible adverse effects inform about teratogenicity Inform patients about the need of contraception/ avoidance of pregnancy Monitor LFT every 2 weeks for 6 months If patients want to become pregnant, wait 2 years or until plasma level is <0.02 mg/l - alternatively treat with cholestyramine or active charcoal for 11 days If pregnancy occurs counsel patient about the possibly of induced abortion MRI yearly Switch to another therapy if unacceptable adverse effect Escalate therapy to a second-line therapy if suboptimal treatment response CBC: complete blood cell count; LFT: Liver function tests; MRI: Magnetic resonance imaging; For alternative treatment: Direct switch to immunomodulator possible
11 Dimethyl Fumarate: benefit/risk evaluation Established Inconveniences and Possible Risks Adverse effects Flushing Abdominal pain Administered as two tablets daily Low risk of PML Established Benefits Robust effect on disease activity Moderate effect on disability progression Numerically but not statistically significant better than GA
12 Recommendations for Maximizing Tolerance and Safety of Dimethyl Fumarate Within 3 months CBC MRI Negative pregnancy test before initiation of therapy in women with child-bearing potential Counsel patients to Report symptoms of infection Report symptoms of any disease worsening Report adverse effects Use contraception/avoid pregnancy Prior to Initiating Initiation During Discontinuation Inform patients about possible adverse effects including rare PML Pregnancy counselling Treat flushing with acetylsalicylic acid Monitor lymphocyte count every 3 months If lymphocyte count < 0.5 x10 9 /l for 6 months, discontinue therapy temporarily MRI yearly Switch to another therapy if unacceptable adverse effect Escalate therapy to a second-line therapy if suboptimal treatment response For alternative treatment: Direct switch to immunomodulator possible CBC: complete blood cell count; MRI: Magnetic resonance imaging; PML: Progressive multifocal leukoencephalitis
13 Fingolimod: Risks/Inconveniences>Benefits Established Inconveniences and Possible Risks Adverse effects Bradycardia, A-V block Retinal edema Infections: dermatomal zoster Infrequent severe adverse effects Serious infections: disseminated varicella, herpes encephalitis Skin cancers Single case of PML Established Benefits Superior to IFN-β 1a Large effect on disease activity Moderate effect on disability progression One tablet daily 13
14 Recommendations for Maximizing Tolerance and Safety of Fingolimod Within 3 months before Tx: CBC LFT and bilirubin levels MRI ECG Ophthalmologic exam in high-risk patients Negative pregnancy test before initiation of therapy in women with child-bearing potential VZV antibody measurement; VZV vaccination if no VZV antibodies Counsel patients to: Report symptoms of infection Report symptoms of any disease worsening Avoid live attenuated vaccines Use contraception/avoid pregnancy Perform: Ophthalmologic exam 3 4 months after starting Tx Spirometry and DLCO when clinically indicated Monitor liver function and blood pressure Prior to Initiating Initiation During Discontinuation CAVE drugs: antiarrhythmics; Ca ++ - channel blockers and β- blockers; inhibitors of CYP3A4-mediated metabolism (avoid, if possible; consult SPC) Pregnancy counselling Inform about possible side effects, including rare PML Baseline pulse and blood pressure Observe all patients for 6 hours with ECG monitoring If symptomatic, extend monitoring and observe until symptoms resolve Tx stopped 1 day in weeks 1-2; > 7 days in weeks 3-4; or > 14 days after week 4: repeat Tx initiation phase Switch to another therapy, if unacceptable adverse effect Switch therapy to another second-line therapy, if suboptimal treatment response 2 months from Tx discontinuation: Monitor for infections Counsel on need for contraception For alternative treatment: 6-week wash-out CBC: complete blood cell count; LFT: Liver function tests; MRI: Magnetic resonance imaging; ECG: Electrocardiography; VZV: Varicella-Zoster virus; CYP: ; SPC: ; DLCO: ; Tx: 14
15 Natalizumab: Benefits>risks/inconveniences Established Inconveniences and Possible Risks Intravenous infusions Rare infusion reactions Rare NAbs Infrequent severe adverse effects PML in 2:1000 per year (after 2 years) Established Benefits Profound effect on disease activity Significant effect on disability progression Improves QoL Good cost-effectiveness Risk stratication for PML possible 15
16 Risk stratification in daily clinical practice JCV Ab JCV Ab+ Tx-naïve patients Breakthrough disease patients High JCV Ab index No previous IS Low JCV Ab index No previous IS Previous IS Rx Natalizumab Use other Rx Rx Na or consider other Rx Use other Rx 6 monthly JCV Ab test After 1 year JCV Ab Continue NaTx JCV Ab+ Recommend other Rx Switch to other Rx Consider other Rx 6 monthly JCV Ab test After 2 year JCV Ab Continue Na Tx JCV Ab+ Recommend other Rx Switch to other Rx Recommend other Rx JCV Ab: John Cunningham virus antibodies; Ab =antibody negative; Ab+=antibody positive; IS: Immunosuppressant therapy; Tx=treatment; Rx=prescription; Na=natalizumab. JCV Ab- JCV Ab+ low index JCV Ab+ high index In all JCV Ab+ patients reconsider natalizumab therapy efficacy of natalizumab Risk assessment in the individual patient with continued Rx Efficacy and risk of alternative treatments
17 Recommendations for Maximizing Tolerance and Safety of Natalizumab Within 3 months before Tx: CBC MRI JCV Ab test Counsel patients to: Report symptoms of infection Report symptoms of any disease worsening Encourage caregiver to report changes in behavior or cognition Use contraception/avoid pregnancy Prior to Initiating Initiation During Discontinuation Inform patients about possible adverse effects including risk of PML Use PML risk stratification Discontinue if hypersensitivity reactions occur Anti-natalizumab Ab testing after 3, 6 and 12 months or if there is ongoing infusion reactions. Cease therapy if test is positive JCV Ab test every 6 months in Ab patients Monitor liver function tests as appropriate MRI yearly If PML is suspected, stop natalizumab, perform MRI and CSF qpcr for JC virus Switch to another therapy if unacceptable adverse effect Switch therapy to another second-line therapy if suboptimal treatment response For alternative treatment: Direct switch to immunomodulator possible Washout prior to immunosuppression, case by case evaluation MRI before start of other treatment CBC=complete blood count; MRI: Magnetic resonance imaging; JCV Ab: John Cunningham virus antibodies; PML: Progressive multifocal leukoencephalitis; Ab: Antibodies; CSF: Cerebrospinal fluid; qpcr: quantitative real-time PCR
18 Alemtuzumab: Benefits>risks/inconveniences Established Inconveniences and Possible Risks Infusion associated reactions Infections Immune thrombocytopenic purpura Immune thyroid disorders Immune nephropaties Cytopenias Established Benefits Robust effect on disease activity and disability progression Infrequent administration Long-lasting efficacy Superiority to IFN-β 1a sc 18
19 Recommendations for Maximizing Tolerance and Safety of Alemtuzumab Within 3 months before Tx: CBC, serum creatinine, urinalysis Thyroid function tests MRI Screening for TB (if indicated) Screening for HBV and/or HIV (if indicated) Screening for VZV antibodies VZV vaccination if no VZ antibodies Negative pregnancy test before initiation of therapy in women with child-bearing potential Counsel patients to: Report symptoms of infection Report signs of bruising, bleedings or petechiae Avoid live attenuated vaccines Use contraception/avoid pregnancy until 4 months after treatment Perform: Monthly CBC, creatinine, urinanalysis Thyroid function tests every 3 months HPV screening annually for female patients. Prior to Initiating Initiation During Discontinuation Inform patients about possible adverse effects Pregnancy counselling (potential adverse fetal outcomes) Antihistamines, corticosteroids and antipyretics prior to infusion Administer corticosteroids first 3 days Pulse and blood pressure monitoring after infusion Oral anti-herpes medication for at least 1 month Tx: ; CBC=complete blood count; MRI: Magnetic resonance imaging; TB: Tuberculosis; HBV: Hepatitis B virus; HIV: Human VZV=varicella-zoster virus; Tx=treatment. 4 years from last treatment: Monitor for infections Monthly CBC, se-creatinine, urinanalysis Thyroid function tests every 3 months For alternative treatment: Only sparse data available; IFN-beta and glatiramer acetate probably safe
20 Thank you for your attention 20
21 Thank you for your attention 21
22 Thank you for your attention 22
Benefit/Risk Strategies in Selecting Therapeutic Solutions for MS: HCP and Patient Viewpoints
Benefit/Risk Strategies in Selecting Therapeutic Solutions for MS: HCP and Patient Viewpoints 1 Learning Objectives Review the benefit/risk strategies in selecting therapy for MS patients while assessing
More informationObjectives. There Aren t Enough Hours in the Day
There Aren t Enough Hours in the Day Medication monitoring and communication of results Objectives Review the types of testing being ordered on patients receiving therapies other than platforms Discuss
More informationPediatric MS treatments: What do you start with, when do you switch?
Pediatric MS treatments: What do you start with, when do you switch? Tim Lotze, M.D. Associate Professor of Pediatric Neurology Texas Children s Hospital Baylor College of Medicine Disclosures Clinical
More informationTREATING MULTIPLE SCLEROSIS The Current Disease Modifying Therapies Beverly Gilder, M.D. Blue Sky Neurology MS Center
TREATING MULTIPLE SCLEROSIS 2018 The Current Disease Modifying Therapies Beverly Gilder, M.D. Blue Sky Neurology MS Center Welcome Thank you for joining us! Today you will learn about MS treatment choices
More informationNDMP Multiple Sclerosis Treatment Protocol. Alemtuzumab THERAPY
Alemtuzumab THERAPY INDICATIONS FOR USE: INDICATION Treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features ICD10 G35
More informationMitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA Disclosures Consultant and Speaker Bureau member for Biogen-Idec, Pfizer, TEVA Neuroscience, Bayer, EMD Serrono, Questcor, Novartis,
More informationMULTIPLE SCLEROSIS - REVIEW AND UPDATE
MULTIPLE SCLEROSIS - REVIEW AND UPDATE Luka Vlahovic, MD Neuroimmunology/Multiple Sclerosis Creighton University Medical Center MS is primary demyelinating disease of the central nervous system. MS is
More informationTreatment monitoring protocol for Dimethyl fumarate therapy in active Relapsing Remitting Multiple Sclerosis
Treatment monitoring protocol for Dimethyl fumarate therapy in active Relapsing Remitting Multiple Sclerosis This protocol provides monitoring guidance for adult patients requiring Dimethyl fumarate therapy
More informationWorkshop II. How to manage highly active MS patients in practice?
Workshop II How to manage highly active MS patients in practice? Gavin Giovannoni Department of Neurology Institute of Cell and Molecular Science Queen Mary University London & Barts and The London NHS
More informationMultiple Sclerosis. Stanley L Cohan, MD, PhD Providence MS Center Providence Brain and Spine Institute
Stanley L Cohan, MD, PhD Providence MS Center Providence Brain and Spine Institute 1 Stanley Cohan conflicts of interest Research Support: Biogen Idec, Novartis, Mallinkrodt, Genzyme, Sanofi-Aventis, Teva,
More informationLocal Natalizumab Treatment Protocol
Local Natalizumab Treatment Protocol 1. New medicine name: Natalizumab 300mg concentrate for solution for infusion (Natalizumab ) 2. Licensed indication(s): Natalizumab is indicated for single disease
More informationPatient 1: 31-Year-Old Female. Fingolimod treatment
Cell Counts (10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Lymphocyte Pharmacodynamics and Safety of Use in Patients Previously
More informationOcrevus. (ocrelizumab) New Product Slideshow
Ocrevus (ocrelizumab) New Product Slideshow Introduction Brand name: Ocrevus Generic name: Ocrelizumab Pharmacological class: CD20-directed cytolytic monoclonal antibody Strength and Formulation: 30mg/mL;
More informationProgress in the field
Progress in the field Eva Havrdová Charles University in Prague 1st Medical Faculty and General University Hospital Disclosures Dr. Havrdová has received consulting fees from Actelion, Biogen Idec, Merck,
More informationMellen Center Approaches: Natalizumab
Cleveland Clinic Mellen Center for Multiple Sclerosis Treatment and Research 216.444.8600 Mellen Center Approaches: Natalizumab Who should be considered for Natalizumab therapy? In the phase II and phase
More informationMS Academia: Multiple sclerosis advanced course
6 October 2015 - Barcelona, Spain MS Academia: Multiple sclerosis advanced course IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Mark S. Freedman University of Ottawa and the Ottawa
More informationFINGOLIMOD (GILENYA) CLINICIAN INFORMATION
What is the medication? Generic: Fingolimod Brand name: Gilenya First oral medication approved by the Food and Drug Administration (FDA) to modify the disease course in multiple sclerosis (MS) Has the
More informationGiancarlo Comi, M.D. On Behalf of the MS-LAQ-301 (ALLEGRO) Study Group. Assessment of oral laquinimod in preventing progression of Multiple Sclerosis
COMPARISON OF EARLY AND DELAYED ORAL LAQUINIMOD IN PATIENTS WITH RELAPSING- REMITTING MULTIPLE SCLEROSIS: EFFECTS ON DISABILITY PROGRESSION AT 36 MONTHS IN THE ALLEGRO TRIAL Giancarlo Comi, M.D. On Behalf
More informationDisease-modifying therapies
Updated May 2018. Please check nationalmssociety.org/dmt for the most current version of this publication. For some people, a diagnosis of multiple sclerosis (MS) is a relief, giving a name and a reason
More informationINITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY INDICATION AUBAGIO (teriflunomide) is indicated for the treatment of patients with relapsing forms of multiple
More informationMellen Center Approach: Lemtrada (alemtuzumab)
Cleveland Clinic Mellen Center for Multiple Sclerosis Treatment and Research 216.444.8600 Mellen Center Approach: Lemtrada (alemtuzumab) Q: What is the mechanism of action of Lemtrada? A: Lemtrada (alemtuzumab)
More informationDimethyl Fumarate (Tecfidera) pathway for Walton Centre MS patients
Dimethyl Fumarate (Tecfidera) pathway for Walton Centre MS patients Author and Contact details: Responsible Director: Ian Pomeroy Service lead for MS. Tel: (0151) 529 5715 Email: ian.pomeroy@thewaltoncentre.nhs.uk
More informationCase Report PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
Case Reports in Neurological Medicine, Article ID 307872, 4 pages http://dx.doi.org/10.1155/2014/307872 Case Report PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation J. Killestein,
More informationPRODUCT MONOGRAPH. Pr GILENYA. Fingolimod capsules mg and 0.5 mg fingolimod (as fingolimod hydrochloride)
PRODUCT MONOGRAPH Pr GILENYA Fingolimod capsules 0.25 mg and 0.5 mg fingolimod (as fingolimod hydrochloride) Sphingosine 1-phosphate receptor modulator Novartis Pharmaceuticals Canada Inc. 385 Bouchard
More informationPRODUCT MONOGRAPH GILENYA. Fingolimod (as fingolimod hydrochloride) Oral capsules, 0.5 mg fingolimod (as fingolimod hydrochloride)
PRODUCT MONOGRAPH Pr GILENYA Fingolimod (as fingolimod hydrochloride) Oral capsules, 0.5 mg fingolimod (as fingolimod hydrochloride) Sphingosine 1-phosphate receptor modulator Novartis Pharmaceuticals
More informationAubagio. Aubagio (teriflunomide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.09 Subject: Aubagio Page: 1 of 6 Last Review Date: June 22, 2017 Aubagio Description Aubagio (teriflunomide)
More informationMultiple Sclerosis: The Safety Efficacy Balance and Preventing Neurodegeneration
Multiple Sclerosis: The Safety Efficacy Balance and Preventing Neurodegeneration Introduction The treatment landscape for multiple sclerosis (MS) has seen extensive growth over the last several decades.
More informationThe invisible facets of MS and everyday challenges clinician s perspective. Mar Tintore
The invisible facets of MS and everyday challenges clinician s perspective Mar Tintore Centre d Esclerosi Múltiple de Catalunya (Cemcat). Department of Neurology/Neuroimmunology Hospital Universitari Vall
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Multiple Sclerosis Agents
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Multiple Sclerosis Agents a. Prescriptions That Require Prior Authorization Prescriptions for Multiple Sclerosis Agents which meet any
More informationSwitching from natalizumab to fingolimod: an observational study
Acta Neurol Scand 2013: 128: e6 e10 DOI: 10.1111/ane.12082 Ó 2013 John Wiley & Sons A/S ACTA NEUROLOGICA SCANDINAVICA Clinical Commentary Switching from natalizumab to fingolimod: an observational study
More informationWelcome to todays Webinar
Welcome to todays Webinar Your Presenter is: Lyndal Emery Your Facilitator is: Andrea Salmon Acknowledgement We acknowledge and pay respect to the traditional custodians past and present on whose lands
More informationDISEASE-MODIFYING THERAPIES FOR MS
DISEASE-MODIFYING THERAPIES FOR MS Updated December 2018. Please check nationalmssociety.org/dmt for the most current version of this publication. A multiple sclerosis (MS) diagnosis can bring a sense
More informationAdvances in the Management of Multiple Sclerosis: A closer look at novel therapies. Disclosures
Advances in the Management of Multiple Sclerosis: A closer look at novel therapies Lily Jung Henson, MD, MMM, FAAN Chief of Neurology Piedmont Healthcare, Atlanta, GA National Association of Managed Care
More informationThe following MS experts were involved in the development of this Position Statement:
Position Statement for TYSABRI (natalizumab) and STRATIFY JCV TM in Multiple Sclerosis Rationale for this Position Statement This Position Statement was developed by ten Australian neurologists who specialise
More informationLife Long Brain Health and DMT Comparative Effectiveness
Life Long Brain Health and DMT Comparative Effectiveness Timothy Vollmer, MD Professor of Neurology University of Colorado Denver Medical Director- RMMSC and Co-Director Rocky Mountain MS Center at CU
More informationTYSABRI Treatment Initiation Form
TYSABRI Treatment Initiation Form This form should be read carefully before starting treatment with TYSABRI. Please follow the advice in this form to ensure that you are fully informed of, and understand
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Multiple Sclerosis (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationConsortium of Multiple Sclerosis Centers 2015 Abstract #3485
Alemtuzumab (ALE) Improves Disability After Switch from Other Disease Modifying Therapies in a High Disability, Treatment Refractory Relapsing MS Cohort Consortium of Multiple Sclerosis Centers 2015 Abstract
More informationDuration of treatment All DMARDs are long term treatments. Clinical benefit may take up to 6 months. 1
Leflunomide Traffic light classification- Amber 1 Information sheet for Primary Care Prescribers Part of the Shared Care Protocol: Management of Rheumatological Conditions with Disease-Modifying Anti Rheumatic
More informationEMA confirms recommendations to minimise risk of brain infection PML with Tysabri
25/04/2016 EMA/266665/2016 EMA confirms recommendations to minimise risk of brain infection PML with Tysabri More frequent MRI scans should be considered for patients at higher risk On 25 February 2016,
More informationFor all requests for Multiple Sclerosis Medications all of the following criteria must be met:
Request for Prior Authorization for Multiple Sclerosis Medications Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Multiple Sclerosis Medications require
More informationProgress in MS: Current and Emerging Therapies. Presented by: Dr. Kathryn Giles, MD MSc FRCPC Cambridge, Ontario, Canada
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC Cambridge, Ontario, Canada Today s Discussion Natural History and Classification of MS Treating MS Management
More informationLe Hua, MD. Disclosures Teaching and Speaking: Teva Neurosciences, Genzyme, Novartis Advisory Board: Genzyme, EMD Serono
Le Hua, MD Le Hua, MD, is a staff neurologist at Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, NV. She is involved in clinical trials assessing new therapies for the treatment of MS and
More informationAubagio. Aubagio (teriflunomide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.09 Subsection: Endocrine and Metabolic Drugs Original Policy Date: April 1, 2013 Subject: Aubagio
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationCurrent Enrolling Clinical Trials
ASSESS RRMS patients with active disease who are still able to walk. Mariko Kita MD Description of Study/Trial: A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization MERC CARE (MEDICAID) Multiple Sclerosis (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationPharmacotherapy Update Multiple Sclerosis
Pharmacotherapy Update Multiple Sclerosis Yolande Hanssens SIG Leader Medicine Information Hamad Medical Corporation Pharmacy Department - Clinical Service Unit Doha - Qatar Heidelberg/October 2017 Pharmacotherapy
More informationNatalizumab (Tysabri; Biogen Idec, Inc, Elan Pharmaceuticals,
n report n Recommendations for the Selection, Treatment, and Management of Patients Utilizing Natalizumab Therapy for Multiple Sclerosis John Foley, MD Abstract Natalizumab is an integrin receptor antagonist
More informationDISCLAIMER FDA INDICATIONS INITIAL COVERAGE CRITERIA POSITION STATEMENT. Subject: Aubagio (teriflunomide) Original Effective Date: 10/30/2013
Subject: Aubagio (teriflunomide) Original Effective Date: 10/30/2013 Policy Number: MCP-146 Revision Date(s): Review Date(s): 12/16/15; 6/15/2016; 3/21/2017 DISCLAIMER This Molina Clinical Policy (MCP)
More informationTRANSPARENCY COMMITTEE Opinion 05 March 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 05 March 2014 AUBAGIO 14 mg, film-coated tablet B/28 tablets (CIP: 3400927499890) Applicant: GENZYME SAS INN ATC code
More informationChoices. Disease modifying treatments. Read me
Choices Disease modifying treatments Read me Disease modifying treatments Disease modifying therapies (DMTs) are medications which modify the course of multiple sclerosis (MS) and are designed to reduce
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationMS Trust Comments on the ACD
MS Trust Comments on the ACD Name xxxxxxxxxxx Role other Other role xxxxxxxxxxxxxxxxxx Location England Conflict no Notes Comments on individual sections of the ACD: Section 1 The MS Trust maintains that
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Multiple Sclerosis Agents (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationBiothérapies et risques infectieux en. neurologie
Biothérapies et risques infectieux en Lieu 14 Date neurologie Patrick Vermersch CHU de Lille XXIIe Journée Régionale de Pathologie Infectieuse Lille, 13 octobre 2015 Liens d intérêts Honoraires, Congrés,
More informationDeaths Patients with events (%) 0 vs. 0 n.r.
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationGilenya Summary of the Risk Management Plan (RMP) v13.1 for Gilenya (Fingolimod)
Drug Regulatory Affairs Gilenya Summary of the Risk Management Plan (RMP) v13.1 for Gilenya (Fingolimod) Document version: 1 Document status: Final Document Date: 14-Feb-2019 1 Summary of the Risk Management
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationVaccinations in MS. Consultant: Accordant, Acorda, Bayer, Biogen, Genentech/Roche, Genzyme/Sanofi, Mylan, Novartis, Serono, Teva
Vaccinations in MS Consultant: Accordant, Acorda, Bayer, Biogen, Genentech/Roche, Genzyme/Sanofi, Mylan, Novartis, Serono, Teva Research: Actelion, Genzyme/Sanofi, Novartis, Opexa 1 Immunobiological product
More informationFAMILY PLANNING AND AUBAGIO (teriflunomide)
FAMILY PLANNING AND AUBAGIO (teriflunomide) INDICATION AUBAGIO (teriflunomide) is indicated for the treatment of patients with relapsing forms of multiple sclerosis. IMPORTANT SAFETY INFORMATION WARNING:
More informationMS Academia: Multiple sclerosis advanced course
13 September 2016 - London, UK MS Academia: Multiple sclerosis advanced course IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Robert J. Fox Assessment of treatment response IMPROVING
More informationUNDERSTANDING HAIR THINNING/HAIR LOSS
UNDERSTANDING HAIR THINNING/HAIR LOSS INDICATION AUBAGIO (teriflunomide) is indicated for the treatment of patients with relapsing forms of multiple sclerosis. IMPORTANT SAFETY INFORMATION WARNING: HEPATOTOXICITY
More informationUpdate in Multiple Sclerosis
Update in Multiple Sclerosis Kyle Smoot, MD Providence MS Center Portland, OR 1 Disclosures Research funds from Biogen. Consulting fees from Acorda, Biogen, EMDSerono, Genzyme, Novartis, and Teva. 2 Outline
More informationMedication Policy Manual. Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 16, 2016 Next Review Date: December 2017 Effective Date: January
More informationTYSABRI (natalizumab) BENEFIT INVESTIGATION WORKSHEET GUIDE
TYSABRI (natalizumab) BENEFIT INVESTIGATION WORKSHEET GUIDE TYSABRI is administered intravenously by a healthcare professional once every 4 weeks. Therefore, a patient treated with TYSABRI will need to
More informationThe Effects of Daclizumab High Yield Process (DAC HYP) on Patient Centered Functional Outcomes: Results From the DECIDE Study
2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers May 27 30, 2015 Indianapolis, IN The Effects of Daclizumab High Yield Process () on Patient Centered Functional Outcomes: Results From
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 16, 2016 Next Review Date: December 2017 Effective Date: January
More informationEfficacy convenience of MS treatments. Xavier Montalban Department of Neurology-Neuroimmunology. ECF Baveno 2013
Efficacy convenience of MS treatments Xavier Montalban Department of Neurology-Neuroimmunology ECF Baveno 2013 Disclaimer Dr. Montalban has received speaking honoraria and travel expenses for scientific
More informationKristen Helms, PharmD Clinical Associate Professor Department of Pharmacy Practice and Office of Teaching, Learning and Assessment Auburn University
Kristen Helms, PharmD Clinical Associate Professor Department of Pharmacy Practice and Office of Teaching, Learning and Assessment Auburn University Harrison School of Pharmacy Auburn, Alabama Presenter:
More informationNEUROLOGY UPDATE IV: MULTIPLE SCLEROSIS
NEUROLOGY UPDATE IV: MULTIPLE SCLEROSIS Learning Objectives Daniel Harrison, MD University of Maryland School of Medicine Baltimore, MD Upon completion of this module, participants should be familiar with:
More informationA Glimpse at Immunomodulators in MS
A Glimpse at Immunomodulators in MS An Interview with Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC Multiple Sclerosis Research Unit, University of Ottowa, Ottowa Canada Ottawa Hospital Research Institute,
More informationEAN Amsterdam June 23-27, 2017
EAN 2017 Amsterdam June 23-27, 2017 MS Nowadays-new goals Giancarlo Comi Dept. of Neurology & Institute of Experimental Neurology Università Vita Salute S.Raffaele, Milano European Charcot Foundation Disclosure
More informationAPPENDIX D SASKATCHEWAN MS DRUGS PROGRAM
APPENDIX D SASKATCHEWAN MS DRUGS PROGRAM PROCEDURE FOR OBTAINING COVERAGE OF MS DRUGS UNDER THE DRUG PLAN Requests are initiated by a physician. The patient and physician complete the application form
More informationThe TOUCH Program and Risk Management. Updated Safety Results From the Use of Natalizumab in Patients With Relapsing Multiple
1 The TOUCH Program and Risk Management Plan for the Administration i ti of Natalizumab: Updated Safety Results From the Use of Natalizumab in Patients With Relapsing Multiple Sclerosis and Crohn s Disease
More informationNeurology and Neurometabolic Unit Department of Neurological and Behavioral Sciences University of Siena Siena, Italy
Nicola De Stefano Neurology and Neurometabolic Unit Department of Neurological and Behavioral Sciences University of Siena Siena, Italy Declared receipt of honoraria or consultation fees from Novartis,
More informationWhen choosing among treatments for
Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate J. Theodore Phillips, MD, PhD; Krzysztof Selmaj, MD, PhD;
More informationMS Treatments Aubagio TM
1 MSology Essentials Series Aubagio TM (teriflunomide) Developed by MSology with the invaluable assistance of multiple sclerosis nurse advisors: Bonnie Blain Central Alberta MS Clinic, Red Deer, Alberta
More informationHot Topics Multiple Sclerosis. Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018
Hot Topics Multiple Sclerosis Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018 Disclosures Natalie Parks has received compensation from Biogen, EMD Serono, Roche, and Sanofi
More informationPresented at the Annual Congress of ECTRIMS, October 11, 2018, Berlin, Germany
Final Results of a Placebo Controlled, Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mab), in Patients with Relapsing Forms of Multiple Sclerosis
More informationMEDIA BACKGROUNDER. Teriflunomide: A novel oral drug being investigated for the treatment of Multiple Sclerosis (MS)
MEDIA BACKGROUNDER Teriflunomide: A novel oral drug being investigated for the treatment of Multiple Sclerosis (MS) 1. Background Teriflunomide is a new oral disease-modifying therapy (DMT), discovered
More informationBiologics and Beyond: Treatment of Multiple Sclerosis. Rita Jebrin, PharmD, BCPS
Biologics and Beyond: Treatment of Multiple Sclerosis Rita Jebrin, PharmD, BCPS Disclosure Information Biologics and Beyond: Treatment of Multiple Sclerosis Rita Jebrin, PharmD, BCPS I have no financial
More informationRegulatory Status FDA-approved indication: Tecfidera is indicated for the treatment of patients with relapsing forms of multiple sclerosis (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.01 Subject: Tecfidera Page: 1 of 5 Last Review Date: December 2, 2016 Tecfidera Description Tecfidera
More informationCarolyn Taylor, M.D. Swedish Neuroscience Center
Carolyn Taylor, M.D. Swedish Neuroscience Center When should disease modifying therapy be discontinued in MS? Should we be using aggressive treatments earlier in the MS disease course and reserving the
More informationAscertaining the Role of the Primary Care Clinician in the Recognition and Management of Patients With Multiple Sclerosis in the Modern Era
Ascertaining the Role of the Primary Care Clinician in the Recognition and Management of Patients With Multiple Sclerosis in the Modern Era Edward J. Fox, MD, PhD MS Clinic of Central Texas Central Texas
More informationClass Update with New Drug Evaluation: Disease-Modifying Drugs for Multiple Sclerosis
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationUpdates to the Alberta Drug Benefit List. Effective August 1, 2018
Updates to the Alberta Drug Benefit List Effective August 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780) 498-8370
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH VIRGIIA Multiple Sclerosis Agents (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationBefore beginning this activity, please be sure to review the learning objectives and faculty disclosures.
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationUNC INFLAMMATORY BOWEL DISEASE DRUG PROTOCOL VEDOLIZUMAB (ENTYVIO)
UNC INFLAMMATORY BOWEL DISEASE DRUG PROTOCOL VEDOLIZUMAB (ENTYVIO) TREATMENT PROTOCOL: Vedolizumab is a humanized immunoglobulin G1 monoclonal antibody that targets 41 integrin and blocks its interaction
More informationSkin Pathway Group Alemtuzumab in Cutaneous Lymphoma
Skin Pathway Group Alemtuzumab in Cutaneous Lymphoma Indication: Treatment of patients with Cutaneous Lymphoma (Unlicensed use) Disease control prior to Reduced Intensity Conditioning Stem Cell Transplant
More informationRegulatory Status FDA-approved indication: Tysabri is an integrin receptor antagonist indicated for treatment of (1):
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.13 Subject: Tysabri Page: 1 of 6 Last Review Date: June 22, 2017 Tysabri Description Tysabri (natalizumab)
More informationEuropean Commission Grants Approval for Mavenclad (Cladribine Tablets)
Your Contact Friederike Segeberg +49 6151 72-6328 Investor Relations +49 6151 72-3321 August 25, 2017 European Commission Grants Approval for Mavenclad (Cladribine Tablets) First oral short-course treatment
More informationReactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2015 Reactivation of herpesvirus under fingolimod: A case of severe herpes
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GILENYA safely and effectively. See full prescribing information for GILENYA. GILENYA (fingolimod)
More informationLong-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing remitting multiple sclerosis: the CLARITY Extension study
753365TAN0010.1177/1756285617753365Therapeutic Advances in Neurological DisordersG Comi, S CooK research-article2018 Therapeutic Advances in Neurological Disorders Original Research Long-term effects of
More informationTreatment Algorithm for Multiple Sclerosis Disease-modifying Therapies
Treatment Algorithm for Multiple Sclerosis Disease-modifying Therapies NHS England Reference: 170079ALG Date Published: 4 September 2018 Gateway reference: 07603 Treatment Algorithm for Multiple Sclerosis
More informationMAVENCLAD. (cladribine tablets) MS Treatments. Produced by Lind Publishing, Inc.
MAVENCLAD (cladribine tablets) Produced by Lind Publishing, Inc. MS Treatments MSology Essentials Series MAVENCLAD (cladribine tablets) Developed by MSology with the invaluable assistance of multiple sclerosis
More information